3.A retrospective analysis of patients with advanced renal cell carcinoma treated with temsirolimus
Journal of University of Malaya Medical Centre 2010;13(1):19-23
The clinical experience of the novel drug temsirolimus on eight patients with metastatic renal cell
carcinoma and who were refractory to other forms of treatment is reported. Although none of the
patients showed complete or partial response, three patients had stable disease. One patient was
prematurely withdrawn due to pneumonitis. Five patients died during the period of observation
of twenty months and the median survival time from start of treatment was ten months. Three
patients showed no evidence of adverse events (AE). Five patients showed dyslipidemia and two
had pneumonitis for which, the drug had to be withdrawn in one of them. None had significant
leucopenia. We conclude that temsirolimus has activity even in heavily pretreated patients in
advanced renal cell carcinoma and in addition, has the benefits of ease of administration and
good tolerability.
Clear-cell metastatic renal cell carcinoma
10.Insomnia in the Elderly: Evaluation and Management
Matthew Joo Ming Ng ; Beng Yeong Ng
The Singapore Family Physician 2021;47(2):19-25
Sleep disturbance is common in the elderly and is frequently undiagnosed. It has been estimated that 75% of adults >65 years of age has sleep disturbance and 30% of them has insomnia. The classification of insomnia has less significance in the older adults as the subtypes demonstrate significant overlap and usually treatment of the underlying disorder does not solve the problem or cure it. The elderly has multiple comorbidities and polypharmacy with a myriad of cause for insomnia. A comprehensive medical and psychiatric history together with a complete physical examination and mental state examination should be done in the evaluation of the older patient. Behavioural therapy with sleep hygiene education should be the initial treatment together with the treatment of the contributing physical and psychiatric conditions. Referral to an expert for cognitive behavioural therapy or multicomponent therapy may be necessary if the initial therapy failed to produce any improvement. If medications are needed it can be combined with behavioural therapy. Medication used should be the lowest effective dose and prescribed for short-term use of not more than 4 weeks. Medications used need to be discontinued gradually and one needs to be mindful of rebound insomnia upon withdrawal. Wherever possible, it will be ideal to avoid benzodiazepines and other sedative hypnotics as first choice for insomnia. Over the counter sleep aids which usually contain antihistamines may not be good choices as they carry significant risk of adverse events and drug interactions. Currently the safest medications for use in the elderly includes the Z-drugs (zolpidem, zopiclone), melatonin and low dose tricyclic antidepressant Doxepin.